Pfizer Inc. (ETR:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 121.21B |
| Revenue (ttm) | 54.48B |
| Net Income (ttm) | 9.18B |
| Shares Out | n/a |
| EPS (ttm) | 1.62 |
| PE Ratio | 13.21 |
| Forward PE | 8.96 |
| Dividend | 1.55 (7.20%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 100,110 |
| Average Volume | 87,910 |
| Open | 21.90 |
| Previous Close | 21.89 |
| Day's Range | 21.45 - 21.99 |
| 52-Week Range | 18.57 - 27.70 |
| Beta | 0.47 |
| RSI | 49.54 |
| Earnings Date | Nov 4, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Lower drug prices for Americans! Trump seals deal with AstraZeneca; some medicines at discounts of up to 80%
President Donald Trump has secured a deal with AstraZeneca. The company will reduce prices on some medicines for America's Medicaid health plan. This agreement follows a similar arrangement with Pfize...
Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.
Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswin...
AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs
Company to sell some medicines at a discount to US’s Medicaid health plan in exchange for tariff relief Donald Trump announced a deal with the British-based drugmaker AstraZeneca for a “most-favored-n...
AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.
AstraZeneca looks poised to announce a deal with U.S. President Donald Trump that’s focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfizer.
AstraZeneca to follow Pfizer lead in making drug price deal with Trump - report
Pfizer (PFE) Target Price Lowered by Morgan Stanley | PFE Stock News
Pfizer (PFE) Target Price Lowered by Morgan Stanley | PFE Stock News
Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports
Trump is set to announce the agreement with AstraZeneca on Friday, after striking a similar deal with Pfizer late last month.
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta
Daily Dividend Report: ZTS,DOW,R,PFE,LMT,NWN
The Board of Directors of Zoetis has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Comp...
Sandoz granted tentative approval for generic of Pfizer's Inlyta
Sandoz gets FDA tentative approval for a generic of Pfizer’s kidney cancer drug Inlyta, but launch is delayed by patent litigation. Read more here.
Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)
Pfizer Inc. remains attractive with strong fundamentals, cost control, an expanding market, and new drugs. Click here to read why PFE stock is a Buy.
Dividend Roundup: Lockheed Martin, Pfizer, Genpact, Delta Air Lines, and more
Pfizer (PFE) Declares Steady Dividend; Yields at 6.81%
Pfizer (PFE) Declares Steady Dividend; Yields at 6.81%
Pfizer declares $0.43 dividend
Pfizer Declares Fourth-Quarter 2025 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company's common stock, payable December 1, 2025, to...
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch
Prescription savings platform GoodRx Holdings Inc. (NASDAQ: GDRX) is reportedly joining the so-called TrumpRx website, signaling an initiative expansion beyond pharmaceutical manufacturers' direct di...
Wilsey Discloses $2.9 Million Purchase of Pfizer Stock Amid Landmark Trump Deal
Updated COVID shot led to less severe illness, fewer hospitalizations last year, US study finds
(Reuters) -Last year's updated COVID-19 vaccines helped prevent severe outcomes including hospitalizations and deaths, according to data from a large study of U.S. military veterans published on Wedne...
Pfizer: Mastering The Art Of The Deal With Metsera - Upgraded To Buy
Pfizer has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders. Click to read why PFE is a Buy.
Pfizer (PFE) Joins Trump's Discount Drug Initiative with TrumpRx
Pfizer (PFE) Joins Trump's Discount Drug Initiative with TrumpRx
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $PFE #ADCs--Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman.
PFE February 2026 Options Begin Trading
Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the February 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, i...
Down 50%, Should You Buy the Dip on Pfizer?
Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.
Pre-Market Most Active for Oct 7, 2025 : TSLL, IONZ, BITF, SLB, IREN, ACHR, TSLQ, AMD, QBTS, LAC, SES, PFE
The NASDAQ 100 Pre-Market Indicator is up 47.65 to 25,026.21. The total Pre-Market volume is currently 151,491,793 shares traded.The following are the most active stocks for the pre-market session: Di...